ABSTRACT
E
ndoscopic transsphenoidal surgery (ETSS) is currently the criterion standard for resecting pituitary adenomas and midline lesions in the complex anatomic location of the anterior skull base. ETSS is minimally invasive, which allows the surgical team to gain an unsurpassed and unobstructed view of the region of interest. [1] [2] [3] During ETSS, a surgical sinonasal corridor is created to access the skull base, often with resection of the nasal turbinates and opening of the paranasal sinus cavities. [4] [5] [6] With alterations to the normal nasal anatomy, concerns have been raised regarding the potential for nasal morbidity and decreased sinonasal-specific quality of life (QoL) after surgery.
In general, the ETSS approach described in the literature differed across institutions. Access to the skull base is described through either a mono-or a binostril approach, retention or resection of the middle and/or superior turbinates, raising or not raising the nasoseptal flap (NSF), and different methods of raising the NSF with either steel or monopolar electrocautery. 7 However, due to concerns for decreasing sinonasal QoL, modifications to ETSS have since been suggested in recent years to potentially decrease nasal morbidity. These have included use of a uninostril approach, preservation of the middle turbinates, avoidance of maxillary antrostomies, and avoidance of raising the NSF. 8, 9 The ultimate goal of ETSS should be the complete achievement of the surgical goals, e.g., total resection of the skull base tumor, in a safe and effective manner. A key consideration is the balance in creating an adequate sinonasal surgical corridor for access against the potential nasal morbidity from increased alterations to the normal nasal anatomy. At our institution, a wide sinonasal corridor is created for the standard ETSS approach, with binostril instrumentation in resecting levels I-II pathology of the anterior skull base. The surgical access is further expanded for levels III-V pathology. 10 With the lack of consensus in the current literature regarding nasal morbidity and inadequate long-term follow-up, additional work within the area of ETSS and patient-based outcomes can help to bridge the gap. Herein, we aimed to examine whether our standard and extended ETSS approach negatively affected patient-specific sinonasal QoL as captured by the validated 22-item Sino-Nasal Outcome Test .
METHODS
This was a prospective cohort study that included patients from the rhinology outpatient clinic at a Canadian tertiary academic center. Our institutional review board approved this study (16-234c) .
Patient Selection
Patients who underwent ETSS from January 1, 2012, to June 30, 2016, were included in the study. All the patients were operated on by the same skull base team of otolaryngologist (J.M.L.) and neurosurgeon (M.D.C.). Only patients who completed both a pre-and postoperative SNOT-22 questionnaire in its entirely were included for data analysis.
Surgical Approach
Our standard ETSS approach, performed since 1993, is centered around creating a wide sinonasal surgical corridor for unrestricted binostril instrumentation and access to the anterior skull base lesion. This approach is used to access levels I and II pathology, and involves a wide bilateral sphenoidectomy, along with the binostril partial resection of the inferior middle turbinates and the inferior superior turbinates. 10 In addition, a wide posterior septectomy is performed. A portion of the septal bone is saved and is often used to reconstruct the defects in the skull base after lesion removal. Routinely, a 15-blade
scalpel and a sickle knife are used to raise a pedicled NSF. Rotation of the NSF is done in both the presence and absence of an intraoperative cerebral spinal fluid (CSF) leak. Silicone sheets are placed at the end of surgery on each side of the septum and sutured with 2-0-gauge polypropylene. Also, the nasal cavity is packed on both sides with petroleum jelly-saturated gauze, placed in a latex-free glove finger. For levels III to V pathology, our extended ETSS is used, whereby additional areas of the anterior skull base are resected to fully access the tumor. 10 The extended approach includes, but is not limited to, opening the skull base through the clivus, planum sphenoidale, tuberculum sellae, pterygopalatine fossa, and cribriform plate. In addition, the ethmoid, maxillary, and frontal sinuses are widely opened to provide unrestricted instrumentation and access. In large skull base defects with a high-flow intraoperative CSF leak, the reconstruction is supported by bilateral Merocel sponges (Medtronic, Fridley, MN) wrapped in a latex-free glove finger and further supported by nasal trumpets.
Postoperative Follow-Up
After ETSS, the patients were started on topical saline solution sprays typically by postoperative day 2. The patients were typically admitted to the hospital overnight for observation and monitoring of bleeding and CSF leak, and, subsequently, discharged home. The first postoperative follow-up occurred at 2-3 weeks, when intraoperatively placed silicone sheets were removed. At this time, the patients were started on high-volume saline solution irrigations. At 3 months after surgery, the patients were seen at the second follow-up appointment, when debridement of sinonasal cavity was performed. They were seen again over 6 months for their third follow-up, when additional debridement was performed if necessary. At all times during the postoperative period, suspected sinus infections were treated with antibiotics and the patients were seen in the clinic for debridement on an as-needed basis.
SNOT-22
The SNOT-22 is a disease-specific, QoL-related measure of sinonasal health, which has previously been psychometrically validated for measuring sinonasal outcomes after surgical interventions (Table 1) . 11-14 SNOT-22 was chosen specifically for its ability to assess sinonasal function, as opposed to other skull base inventory and/or instruments that assess outcomes less relevant to sinonasal health. 15, 16 Higher scores correlate with greater sinonasal-related health burden. Normal SNOT-22 scores range from 11 to 16. 17 Subanalysis of sinonasal symptoms (questions 1-8) was performed in addition to analysis of the overall SNOT-22 score. 18 
Outcome Measures
The primary outcome measure was the SNOT-22 score, before and after ETSS. The SNOT-22 questionnaire was routinely administered during all patient visits to the rhinology outpatient clinic and was completed prospectively. The preoperative SNOT-22 score was determined as the most recent completed questionnaire before surgery. Scores at follow-up intervals were captured and grouped into three quantiles: 0-1, 2-4, and Ͼ5 months. Additional outcome measures included baseline demographic data (age, sex), tumor pathology (pituitary adenoma; meningioma; craniopharyngioma; and other lesions, e.g., schwannoma, chordoma, encephalocele, Rathke cleft cyst), the ETSS procedure extent (standard and extended), the presence of 
Statistical Analysis
Statistical analyses were performed by using SAS 9.4 (SAS Institute Inc, Cary, NC) with statistical significance set at ␣ ϭ 0.05. The results were reported as mean Ϯ standard deviation. The patients who had more than one SNOT-22 questionnaire completed during a single follow-up interval had scores averaged for analysis. The mean SNOT-22 scores at pre-and postoperative follow-up time points (0-1, 2-4, and Ͼ5 months) were compared by using one-way analysis of variance with the least significant difference post hoc testing to determine differences between paired follow-up intervals. Multiple comparisons were conducted to assess the difference in the mean SNOT-22 scores across study variables (standard versus extended ETSS, tumor pathology, the presence of CSF leak and repair, and previous nasal surgery) at each follow-up time. A general linear model was used to compare SNOT-22 scores by follow-up interval and surgery method.
RESULTS
A total of 249 ETSS cases were identified within the 3.5-year span. Of these, 148 patients (59%) had at least one completed SNOT-22 questionnaire; 45 (18%) met the inclusion criteria. Baseline characteristics for both included and excluded patients are summarized in Table 2 . The follow-up time ranged from 2 weeks to 24 months for the included patients. The patients who had multiple SNOT-22 scores during a single follow-up interval (n ϭ 11) had their follow-up times averaged. This resulted in 24, 32, and 21 SNOT-22 scores analyzed in the 0-1, 2-4, and Ͼ5 months follow-up intervals, respectively. The number of follow-up surveys completed did not affect the SNOT-22 scores, p Ͼ 0.05. Postoperative complications were rare; one patient (2%) required additional surgical closure for CSF leak.
When comparing SNOT-22 scores across follow-up intervals ( Fig. 1  A) , there was a significant score increase of 12% in the total score from preoperative levels (27.1 Ϯ 19.3) to 0-1 month after ETSS (40.5 Ϯ 22.5; p Ͻ 0.05). SNOT-22 scores decreased by 13%, from 0-1 to 2-4 months (25.9 Ϯ 17.3; p Ͻ 0.05), which returned to preoperative levels (p Ͼ 0.05). SNOT-22 scores remained at preoperative levels at Ͼ5 months (24.6 Ϯ 19.3; p Ͼ 0.05). When evaluating nasal-specific symptoms (SNOT-22 questions 1-8) scored of 40 (Fig. 1 B) , the score increase of 17% from before ETSS (8.62 Ϯ 7.63; p Ͻ 0.05) to 0-1 month (15.6 Ϯ 8.49) was significant (p Ͻ 0.05). At 2-4 months (10.8 Ϯ 8.17), symptoms improved significantly, with a 12% decrease (p Ͻ 0.05), returning to baseline preoperative levels (p Ͼ 0.05). This improvement in symptoms persisted at Ͼ5 months (10.3 Ϯ 7.37; p Ͼ 0.05).
For olfaction (SNOT-22 question 5) scored out of a maximum of 5 points (Fig. 1 C) , there was a significant increase, of 37%, at the 0-1 month follow-up (2.71 Ϯ 1.75) from pre-ETSS levels (0.844 Ϯ 1.35; p Ͻ 0.05). By 2-4 months (1.56 Ϯ 1.63), olfaction improved with a 23% decrease in the score, back to preoperative levels (p Ͼ 0.05). At Ͼ5 months after ETSS (1.55 Ϯ 1.47), olfaction was retained compared with the baseline score (p Ͼ 0.05). In a multivariate analysis (Table 3) , the patients who had an extended ETSS did not have higher SNOT-22 scores compared with patients who had a standard ETSS across follow-up time intervals (p Ͼ 0.05); this is illustrated in Fig. 2 . Similarly, the presence or absence of an intraoperative CSF leak repair or previous surgery through the nose did not affect the preoperative or follow-up scores (p Ͼ 0.05). The type of tumor pathology, when comparing pituitary adenoma against all other lesions was found to not influence the SNOT-22 score before surgery and at follow-up (p Ͼ 0.05). 
D O N O T C O P Y

DISCUSSION
The goal of the minimally invasive endoscopic approach to the skull base is to resect the lesion and disease of interest while doing the least harm to the normal surrounding structures and the patient. [1] [2] [3] There is a direct tradeoff between optimal visualization of the skull base and the need for additional removal of normal anatomic structures. 5 In comparing our pre-and postoperative follow-up SNOT-22 scores to those reported by McCoul et al., 19 we noted that our patients had a higher baseline score, of 27.1 Ϯ 19.3, compared with 17.5 Ϯ 16.7. Despite the baseline differences, the relative changes in the SNOT-22 scores were comparable at all follow-up time points. 19 Although our reported cohort had higher SNOT-22 scores at baseline, the relative change was the same. This may add further evidence that QoL was retained after ETSS even in the patients with worse baseline sinonasal symptoms.
Our standard approach may be considered by some surgeons to be more aggressive in creating a wide sinonasal surgical corridor. In contrast, Thompson et al. 8 reported on conservative modifications to ETSS by retaining the nasal turbinates and by using an NSF only when a CSF leak was encountered, and found a decrease in sinonasal burden when compared with their standard ETSS approach. Hong et al. 20 noted that transnasal transseptal approaches to the sella had better sinonasal QoL due to added preservation of sinonasal mucosa. However, analysis of our results showed that, even with partial resection of the middle and superior turbinates and routinely elevating an NSF, sinonasal QoL was only temporarily disturbed in the postoperative period. Moreover, elevation of the NSF has previously been shown to not adversely affect olfaction after ETSS. 21, 22 When we evaluated our extended ETSS approach, where there was a significantly wider opening of the anterior skull base and the adjacent paranasal sinuses, it was reassuring to find that sinonasal QoL still returned to preoperative levels in as little as 2 months after surgery. Analysis of our data provided support to the argument for obtaining wide exposure for optimal visualization and instrumentation versus conservative surgical corridors for minimizing nasal morbidity. With a standardized postoperative protocol for surgical healing, sinonasal health should be expected to return to baseline levels by 2-4 months, even with extended ETSS approaches.
Although studies explored sinonasal morbidity after ETSS, currently there is still debate about the evidence and a lack of literature that explores potential morbidity of more extensive approaches to the skull base. Rotenberg et al. 23 reported that olfaction as measured by the University of Pennsylvania Smell Identification Test was significantly decreased at 7 months after the surgery for patients with pituitary adenoma compared with baseline levels. However, conflicting results were noted by Hart et al., 24 who showed a return of olfaction to baseline levels at 3 months after surgery in patients with pituitary tumors measured with the University of Pennsylvania Smell Identification Test.
There also were conflicting results from investigators who reported on patient-based QoL after ETSS. Although some investigators found no change from preoperative levels to 2-4 months after surgery, 18, 25 others found significant deterioration in sinonasal QoL after the operation. 26, 27 With conflicting results, the current studies do not fully address questions about the potential for morbidity for patients undergoing ETSS, especially for the patient who will be undergoing more extensive surgeries. Our study provided potential answers in addressing this gap in the literature, reiterating that, even with the creation of a wide sinonasal corridor, sinonasal-specific QoL should be maintained in the long term.
In addition, many of the current studies published on sinonasal morbidity after ETSS are limited by small samples sizes and short follow-up times. Sowerby et al. 18 reported on sinonasal morbidity after ETSS and found no changes in the SNOT-22 score after ETSS. However, this study was limited by its sample size of 22 and average follow-up of Ͻ2 months. 18 Wang et al. 25 found that SNOT-22 scores for patients with pituitary adenomas worsened 1 week after ETSS but improved to preoperative levels at 1 month. Again, a limiting factor was a relatively short follow-up duration, the maximum of which was 4 months. 25 Kuan et al. 28 evaluated QoL after ETSS and found no changes in scores at a mean of 7 months. However, only 10 patients had completed both pre-and postoperative SNOT-22 questionnaires. 28 To our knowledge, our series was one of the largest and had one of the longest mean follow-ups of completed SNOT-22 questionnaires in the patients who underwent ETSS.
There were several limitations to the study. Although 59% of all the patients who had ETSS completed at least one SNOT-22 questionnaire, there were only 45 patients (18%) who had both pre-and a postoperative scores. The low response rate may have contributed to selective bias. However, when we compared baseline demographics between the included and the excluded patients, we found that there were no significant differences between the groups. Moreover, we were made aware of limitations with the collection process of the SNOT-22 scores. Although the questionnaire was given at each patient visit, some questionnaires were incompletely filled out or were improperly scanned into the electronic medical records. This highlighted the need for further instructions to patients and supporting office staff and is an area that can be actively addressed in future studies.
CONCLUSION
Our standard and extended ETSS approach with a wide sinonasal surgical corridor did not seem to affect sinonasal QoL for patients in the long term. Additional factors, including the extent of surgery, CSF repair, previous sinonasal surgeries, or type of skull base lesion, did not affect patient-based sinonasal QoL. Nasal morbidity after ETSS seemed to only be transient, and patients should be expected to recover to preoperative levels within 2-3 months after surgery. 
